FDA advisory committee recommends approval of Jardiance(R) (empagliflozin)
A FDA Advisory Committee voted 12-11 that substantial evidence exists to establish that Jardiance® (empagliflozin) reduces cardiovascular death in adults with type 2 diabetes and established CV disease. JARDIANCE is marketed by Boehringer Ingelheim and Eli Lilly. June 28, 2016